DYN.US Dyne Therapeutics Inc

Healthcare Biotechnology USA Stocks
17.16 USD
Close of Nov 13, 2026
14.00 27.31
Market cap
USD 3.22B
P/E
-
P/B
3.43x
ROE
-70.6%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is DYN.US undervalued?

Graham number

The Graham number of Dyne Therapeutics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Dyne Therapeutics Inc fundamental analysis

No fundamental analysis for Dyne Therapeutics Inc yet.

Dyne Therapeutics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Dyne Therapeutics Inc

Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that del…

Full company profile